Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
Objective. To evaluate safety and efficacy of intravenous ferric carboxymaltose (FCM) versus standard medical care (SMC) for iron-deficiency anemia (IDA) in postpartum women and women with heavy menstrual bleeding. Study Design. This open-label, multicenter study randomized women with IDA (hemoglobi...
Saved in:
Main Authors: | Melvin H. Seid, Angelia D. Butcher, Ashwin Chatwani |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Anemia |
Online Access: | http://dx.doi.org/10.1155/2017/9642027 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia
by: Iftikhar Hussain, et al.
Published: (2013-01-01) -
REGAIN STUDY: Retrospective Study to Assess the Effectiveness, Tolerability, and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia in Pregnant Women
by: Saleema Wani, et al.
Published: (2019-01-01) -
Ferric Carboxymaltose in the Management of Iron Deficiency Anemia in Pregnancy: A Subgroup Analysis of a Multicenter Real-World Study Involving 1191 Pregnant Women
by: Prakash Trivedi, et al.
Published: (2022-01-01) -
The experiences of ferric carboxymaltose desensitization and provocation
by: Fatma Dindar Çelik, MD, et al.
Published: (2025-02-01) -
Danger of co-administration ferric carboxymaltose and denosumab: hypophosphatemia
by: Aysun Seker, et al.
Published: (2025-01-01)